Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Cancer|March 30, 2025
Upfront intensive treatment analysis of the Italian Cohort Study on FLT3-mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real-life settingJacopo Nanni, Irene Azzali, Cristina Papayannidis, et al.
Cancers|September 28, 2023
Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All StudyNicola Stefano Fracchiolla, Mariarita Sciumè, Cristina Papayannidis, et al.
Cancer|August 21, 2025
Gilteritinib in FLT3-mutated acute myeloid leukemia: A real-world Italian experienceRoberto Cairoli, Lorenzo Del Castello, Silvia Imbergamo, et al.
British Journal of Haematology|November 6, 2022
Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front-line with paediatric-inspired regimens: A retrospective multicentre Campus ALL studyMichelina Dargenio, Massimiliano Bonifacio, Sabina Chiaretti, et al.
Cancer|March 22, 2025
INO-CD22: A multicenter, real-world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemiaCristina Papayannidis, Elisabetta Petracci, Patrizia Zappasodi, et al.
Haematologica|August 29, 2020
Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06Chiara Caprioli, Federico Lussana, Silvia Salmoiraghi, et al.
Cancers|June 24, 2022
Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 ProtocolMonica Messina, Alfonso Piciocchi, Tiziana Ottone, et al.
American Journal of Hematology|January 20, 2025
Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating AgentsGiovanni Marconi, Elisabetta Petracci, Giuseppe Lanzarone, et al.
The Lancet. Oncology|April 7, 2009
Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II studyFabio Ciceri, Chiara Bonini, Maria Teresa Lupo Stanghellini, et al.
Hematological Oncology|August 7, 2019
Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapyMonica Bocchia, Anna Candoni, Erika Borlenghi, et al.
Pageof 5